Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I never seriously entertained the probability of JJ deliberately sabotaging deals in favor of diluting the share structure in order to keep the ATM going.
You'd think someone of my advanced age would know better.
Better late than never..
I could live with "pie in the sky" deal making, but the thought of setting up these "faux deals" as you describe them makes me feel ill. Your premise could be correct. A shrewd attorney like JJ would never seriously consider a man like Ulander to be above suspicion.
If this is true, shame on me for being fooled and shame on this man for treating his loyal North American "friends" in such a way.
Six months sounds about right. Who has the stomach for more than an additional twenty-five "next weeks?"
BB, Can you give us some solid information on when AUYRN will resume drilling and exploration of the ADL properties?
You indicate from past posts that you have knowledge of unpublished information regarding this.
You are correct in assuming that I am a simple investor. I cannot adequately address your question.
I can only state my case for RGBP by examining my own investing history.
Although biotech is not my forte, I have nonetheless had remarkable success investing in this sector, currently holding 10 baggers in AMB$ and ADX$. I have done very well with $TIX and I expect $OMA to be my next success. Not to brag, but these are recent examples that you can confirm by checking my record of posts.
Call it blind luck, but I've done well with biotech over the years. I don't know why this should be, other than to say I've been able to find companies with breakthrough technologies or with strong personnel. Not understanding the science, I place my faith in part on the record of achievement of company officers.
With Dr.'s Koos and Ichim, there is indeed a mixed bag. In my opinion, The strength of Dr. Ichim's resume wins out.
Molybdenum’s price is down in the dumps along with most of the rest of the commodity sector. All of the metals are down today.
Isn't investing about making money?
I'd say that JJ's stalling has cost us dearly.
My response is in part based on progress on animal and pre-clinical studies, namely Hema's pre-clinical proof of concept which has been demonstrated and is a component leading to FDA process for IND approval.
In larger part, my enthusiasm for the company finds root in Regen's mission statement: "Putting together the brightest
minds involved in basic science, drug development, medical
practice and commercialization to develop new cures in the most
rapid means possible."
These cures lie in the exciting and ground-breaking fields of gene silencing therapy and stem cell treatments and are being directed under the scientific leadership of highly regarded researcher and inventor Thomas E.Ichim. Dr. Ichim has taken the role of co-manager of Regen.
Fellow scientists recognize Thomas E.Ichim as a respected leader in his field, having published 91 peer-reviewed articles and who has generated 30 patents and patent applications.
Bloomberg's Executive Profile gives us a resume that is stunning in regard to achievement: "Dr. Thomas E. Ichim, PhD has been the President and Chief Scientific Officer at Medistem, Inc., since October 6, 2012. Dr. Ichim is a Co-founder of bioRASI. Dr. Ichim is the founder of ToleroTech Inc., OncoMune LLC and MedVax Pharma Corp. He has been Director of Research and Chief Scientific Officer of Regen BioPharma Inc. since June 15, 2012. Dr. Ichim serves as the Chief Scientific Officer of bioRASI, LLC. Dr. Ichim has been the Chief Executive Officer of Medistem, Inc., since March 2008 and served as its Chief of Scientific Development since January 2007. He is a seasoned biotechnology entrepreneur with a track record of scientific excellence. Dr. Ichim served a variety of instrumental roles for companies operating in the area of biologics. He obtained numerous regulatory approvals for companies such as MarrowTech Pharma and served as a Program Director for the global CRO bioRASI, under which he led efforts to develop, clinically assess, and approve various stem cell and cellular therapies. He is an accomplished Scientist with 15 scientific papers published in areas ranging from immunological tolerance, to cancer therapy, to autoimmunity. He serves as a Director of Medistem, Inc. He serves as a Member of Advisory Board at Cromos Pharma,LLC. He serves as a Member of the Scientific Advisory Board at Orcrist Bio Inc., Entest, and MBVax Bioscience Inc. He is an ad-hoc editor and sits on several editorial boards. He has co-authored many scientific journal articles and is a peer reviewer for several scientific journals in the area of immunology and translational medicine. He is a member of Vendevia Group. He has been a Director of Regen BioPharma Inc. since July 15, 2013."
Doctors Min, White, and Suhy serve on the advisory board.
I would argue that the scientific strength of the organization is impressive and lies with Dr. Ichim and the advisory board.
What impresses me also is the progress made to date on Regen's Operational Plan. Per their published timeline, Inlicensing of Intellectual Property, "Having already assessed over 20,000 issued patents and having compiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses on issued patents that have already passed preclinical studies but are not under clinical development." This is followed on the timeline by Interaction with Regulatory Agencies "Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials."
These important milestones in their Operational Plan have been accomplished. "Next up" is Clinical Implementation. We all know what that represents.
You're wrong. It's a winner.
We are on a Great Journey...
with much moving forward behind the scenes... that we will all be privy to one of these days...
Word up! RGBP/BMSN could be the surprise sleeper biotech success story of the year...
It's Kool-Aid only if emotional attachments allow it to be Kool-Aid...
We have a problem here in that just about everyone currently invested in this stock is under water. With no progress in exploration or negotiations being reported, we seem to be stalled out with nothing but "Kool-Aid" to sustain us on the "never-ending journey."
What hype...??? Followed by what disappointment...???
The attitudes of our fellow investors have increasingly turned to resignation over the low share price.
In my opinion, were it not for the weekly doses of "Kool-Aid," we would not be subject to this ongoing cycle of hype followed by disappointment. This questionable promoting will eventually end once this resource falls into better hands.
Mining exploration is a slow business. Development is even slower. A realistic appreciation of this fact would serve us better than the continually unmet expectations shareholders are currently saddled with.
It's easy to see why, with the Caren vein reporting over 600 grams per ton, interest has been high in this part of the ADL. I have been very keen on learning more about the high-grade bulk sampling program supposedly centered on this vein, but there have been no recent updates on progress.
I believe the impressive examples you supply are for high tonnage deposits. Of course, the Caren vein is about 1500 meters long and relatively narrow in width so the grade, although stunning, represents limited tonnage. Dr. DeCosta describes the possibility of a couple dozen of these "veims" scattered in a trend from the LDM to the La Fortuna sites. Speculation is that the Caren is the first discovered of several high grade veins.
Hi BB...
Still not sure why the Kool-Aid tastes so good.
To drink the Kool-Aid is "to support or believe in something in a blindly enthusiastic way."
-dictionary.reference.com/browse/kool-aid
Who wants to go "halfs" on Fiji?
Ahhhhhhhhhhhh... it tastes.... Soooooooooooooo Gooooooooooooooooooddd...!!!
It is nothing short of phenomenal, this return, week after week, year after year to the same old frosty pitcher.
Although it would be great if this time were different, nothing new has been offered in the way of solid information, just the same rumor mill with probably the same place of origin.
Fool me once, shame on you, fool me countless times over the span of years, well, that's just incredible. And I feel incredibly stupid for having begun to buy into the latest spin.
If nothing is heard by Friday, we'll chalk it up to another "next week."
IMHO
I'm pleased as punch!
In early clinical drug development, Proof of Concept is usually demonstrated in Phase I and Phase II. It is interesting that the article describes this POC as being derived from preclinical data of DiffronC technology.
At any rate,things sound like they're really cooking at the lab!
All joking aside, the advice is very good.
I have long suspected that "buy low, sell high" was the key to success in investing.
Problem is, the "devil is in the details."
I'd wager that libraries have been written and lifetimes spent trying to put this simple principle into practice.
However, now that the key to success has been revealed, I feel that we are halfway there!
Priceless!
It's still a great resource, Beth. Just a shame about how it's been monetized to date.
I know you're with me on this: Let's get down to some serious exploration and cut the monkey business. Next up..AUYRN!
Looks like booty is being accumulated this morning.
I completely agree with you when you state that the average Medinah shareholder is "just over their heads in an arena/area they have little understanding of."
It is best if one has some knowledge of the sector being invested in. In Medinah's case, a little knowledge of say, geology, plate tectonics, and mining methods goes a long way toward making an informed decision.
Of course, the biggest mistake of many investors here has been allocating too much money to one stock and buying at levels that are too high.
Of course many have simply hitched their wagons to a dream. When this occurs en masse, there are certainly plenty of outlaws on the ready to rob the wagon train...
Up $1.77/pps in premarket this morning. Some bullish investors have called a bottom.
We're in much better company:
www.otcmarkets.com/research/otcqx-company-list
Of course, the many prestigious foreign companies that list on the OTCQX do so to avoid the high costs associated with listing their shares on a large U.S. exchange like the NYSE.
Nonetheless, this is important to note:
"The OTCQX Marketplace provides a number of advantages to investors. It separates out the superior companies from the numerous OTC companies that are either financially challenged or are involved in questionable activities or both."
www.investopedia.com/terms/o/otcqx.asp
Always stoked, never jaded.
Happy to say cost basis was just about 0.055/pps. Would have been a nickel except for one buy at 0.12 when the hype got the better of me.
Many thanks go out to our charting guru HR for keeping me on the straight and narrow with his excellent notes on MACD crossover data.
You're not doing too badly. Am very surprised to read of many who bought big at 0.11 to 0.19. There are probably a few hanging around who got in long ago after the LP scandal. Now that would have an opportunity for a smart trader to unload at the time of the "done, done, done" Shareholder's Meeting.
Wake it up with a little boom shakalaka laka, BOOM Shakalaka laka BOOM shakalaka laka and Repeat 24/7 to keep the price above 0.025/pps.
Regarding the request for proof of the statements you put forward recently regarding AUYRN’s progress in drilling and exploration over the past two months, some explanation is in order.
I was simply asking if your statements were actual facts, and if so, to offer proof of same.
A fact is defined as a truth known by actual experience or observation. I suppose something could be called a fact if it known or observed by a person of impeccable standing, a scientist or other impartial observer whom we trust, and whom we have no reason to doubt.
To use the analogy of gold reserves, for an opinion or viewpoint to move from the inferred to proven category requires a bar that is set very high.
So, long story short, we are stalled out here on a definition. To make my position clear, I am very enthusiastic about this collection of claims and have been since I’ve been able to evaluate the facts that exist up to this point in time. All that’s lacking is proof, and that’s going to require a lot more exploration and drilling, neither of which can be proven to have taken place over the past two months. I’ll be very happy if this changes.
Sorry if that offends you but that is a fact anything beyond that fact is pure speculation!
the facts indicate that nothing has slowed down at this point within the confides of the season
And you believe that MDMN can release any information on the Auyrn deal without Auryn's approval..
I have been involved in many joint ventures and the controlling party is the party with the money and they usually control all information about the project. So MDMN can not release any information relating to the projects without Auryn's approval. If you believe otherwise I suggest you do a little DD on JV agreements and joint project agreements and who controls the press
It is you opinion otherwise prove it is fact!
And why would they release positive information while they are trying to negotiate with JJ.
If progress was being made on either the Caren vein's high grade bulk sampling program, porphyry drilling, or drilling of low grade ore bodies on the ADL, we surely would have heard mention of it via the MDMN Shareholder's Updates. It would be in MDMN's best interest to do so.
I am not expressing an opinion.
I am stating fact, not conjecture, based on what is published and available to the public.
If you have evidence to the contrary, please present it.
Yes they do when it says underway!
It stands to reason that any positive developments are going to be published by MDMN to support the share price during this stagnant period. They have given us nothing in the way of exploratory progress in two months.
AUYRN has said nothing since May 7th.
Recall that this is stated concerning the hiring of porphyry expert Luciano Bocanegra:
"The team will welcome his contribution to the aggressive program that is currently underway."
Now the mention of an "aggressive program" does not necessarily mean that aggressive efforts are in progress at the current time. I believe that will change and I sincerely hope for newsworthy progress soon and the best to all MDMN shareholders!
I stated that we have nothing in the way of exploration results in the published material over the past two months. Hirings, IR firms and planned commencement of bulk sampling are not the same as active exploration.
I'm afraid that any statements made by anyone indicating active exploration at this time can not be substantiated. That's it.
Wish it were otherwise, but we must face the facts.
Said execution will NEVER commence until JJ gets the heck out of the way.
Kramer says "no" in the lightning round.
www.cnbc.com/id/
Time to "buy buy buy" ahead of EYEGUARD-B RESULTS...
IMHO
Time to add. Soon as I can knock some change loose...